Anavex Life Sciences (AVXL) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Anavex Life Sciences is set to announce its Q3 2025 earnings on August 5th, with analysts predicting a loss of ($0.13) per share.
• The company's shares recently opened at $11.57 with a market capitalization of approximately $988.31 million.
• Following a recent increase in stake by a hedge fund, 31.55% of Anavex's stock is owned by institutional investors.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) is expected to post its Q3 2025 quarterly earnings results before the market opens on Tuesday, August 5th. Analysts expect Anavex Life Sciences to post earnings of ($0.13) per share for the quarter.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. During the same period in the previous year, the firm posted ($0.13) earnings per share. On average, analysts expect Anavex Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Anavex Life Sciences Stock Performance

NASDAQ AVXL traded down $0.10 during trading hours on Friday, reaching $11.20. The company's stock had a trading volume of 866,336 shares, compared to its average volume of 1,142,678. The company's 50-day moving average is $9.65 and its two-hundred day moving average is $9.15. Anavex Life Sciences has a fifty-two week low of $4.93 and a fifty-two week high of $14.44. The stock has a market cap of $956.70 million, a PE ratio of -20.36 and a beta of 0.72.

Hedge Funds Weigh In On Anavex Life Sciences

A hedge fund recently raised its stake in Anavex Life Sciences stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 10.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 50,525 shares of the biotechnology company's stock after acquiring an additional 4,869 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.06% of Anavex Life Sciences worth $434,000 as of its most recent SEC filing. 31.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AVXL has been the subject of a number of recent research reports. D. Boral Capital reissued a "buy" rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research note on Monday, April 7th. HC Wainwright reissued a "buy" rating and set a $42.00 price target on shares of Anavex Life Sciences in a research report on Monday, April 7th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.